Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Average PT from Analysts

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has been given an average rating of "Buy" by the seven research firms that are covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $85.67.

Several research firms have commented on GPCR. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. Morgan Stanley began coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They issued an "overweight" rating and a $118.00 price target for the company. Finally, HC Wainwright initiated coverage on Structure Therapeutics in a research note on Wednesday, December 4th. They set a "buy" rating and a $80.00 price objective on the stock.

Structure Therapeutics Price Performance

Shares of NASDAQ GPCR traded down $0.46 during midday trading on Friday, reaching $31.25. 499,739 shares of the stock traded hands, compared to its average volume of 787,025. The company's 50 day moving average is $36.32 and its 200 day moving average is $39.19. Structure Therapeutics has a one year low of $26.61 and a one year high of $62.74. The stock has a market capitalization of $1.79 billion, a PE ratio of -42.23 and a beta of -3.41.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP increased its position in shares of Structure Therapeutics by 2.9% during the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company's stock worth $341,015,000 after acquiring an additional 221,851 shares during the period. FMR LLC increased its holdings in Structure Therapeutics by 6.7% during the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company's stock worth $268,977,000 after purchasing an additional 383,635 shares during the period. Janus Henderson Group PLC raised its position in Structure Therapeutics by 18.0% during the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company's stock valued at $173,623,000 after purchasing an additional 602,609 shares in the last quarter. Driehaus Capital Management LLC lifted its holdings in shares of Structure Therapeutics by 3.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company's stock worth $101,204,000 after buying an additional 86,833 shares during the period. Finally, Federated Hermes Inc. grew its position in shares of Structure Therapeutics by 6.6% during the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company's stock worth $94,531,000 after buying an additional 150,000 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.